- Clinical need
- About MicroRNAs
- Test technology
- How the test is performed
- For which patients
- Results overview
- Today's diagnostic solution
- How to order
- News and publications
- miRview® home
The next generation of
cancer diagnostics is here
cancer diagnostics is here
Introducing miRview® lung
Rosetta Genomics is pleased to introduce
the next generation of cancer diagnostics: microRNA assays.
Rosetta Genomics is pleased to introduce
the next generation of cancer diagnostics: microRNA assays.
|
miRview lung is a cutting-edge molecular diagnostic test that uses microRNA to accurately differentiate Small Cell Lung Cancer (SCLC), carcinoid, squamous Non Small Cell Lung Cancer (NSCLC) and non-squamous NSCLC, helping you make informed decisions. unlike current methods, miRview® lung provides a differential diagnosis with fast, standardized and objective classification.
The highest level of accuracy demonstrated by the validation study performed on 451 independent samples. This study determined the test's sensitivity and specificity to be 93.7% and 98%, respectively1.
|